The Chemours Company (NYSE:CC) Receives Consensus Recommendation of “Hold” from Analysts

Shares of The Chemours Company (NYSE:CC) have received a consensus rating of “Hold” from the eight brokerages that are presently covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $24.88.

A number of research analysts have recently issued reports on CC shares. Barclays boosted their price objective on Chemours from $21.00 to $23.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Royal Bank of Canada reissued an “outperform” rating and issued a $25.00 price target on shares of Chemours in a research note on Thursday, December 12th. Morgan Stanley cut their price target on Chemours from $30.00 to $25.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 5th. The Goldman Sachs Group lowered their price objective on shares of Chemours from $29.00 to $23.00 and set a “neutral” rating for the company in a research note on Tuesday, September 3rd. Finally, BMO Capital Markets increased their target price on shares of Chemours from $30.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, October 7th.

Chemours Stock Performance

NYSE:CC opened at $17.01 on Friday. The company has a market capitalization of $2.54 billion, a PE ratio of 34.02 and a beta of 1.80. Chemours has a fifty-two week low of $15.10 and a fifty-two week high of $32.70. The company has a debt-to-equity ratio of 6.05, a quick ratio of 0.92 and a current ratio of 1.73. The company has a 50 day simple moving average of $19.49 and a two-hundred day simple moving average of $20.36.

Chemours (NYSE:CC) last posted its quarterly earnings data on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.08. The company had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.44 billion. Chemours had a net margin of 1.34% and a return on equity of 29.48%. Chemours’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.64 earnings per share. Research analysts anticipate that Chemours will post 1.35 earnings per share for the current year.

Chemours Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Friday, November 15th were given a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 5.88%. The ex-dividend date of this dividend was Friday, November 15th. Chemours’s payout ratio is presently 200.00%.

Insider Buying and Selling

In related news, SVP Alvenia Scarborough sold 7,500 shares of Chemours stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $20.64, for a total transaction of $154,800.00. Following the transaction, the senior vice president now owns 16,645 shares of the company’s stock, valued at $343,552.80. The trade was a 31.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.47% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Chemours

Several large investors have recently bought and sold shares of CC. Matrix Trust Co purchased a new position in shares of Chemours in the 3rd quarter worth approximately $25,000. Blue Trust Inc. lifted its holdings in Chemours by 166.9% during the third quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company’s stock worth $26,000 after acquiring an additional 731 shares during the period. Truvestments Capital LLC bought a new position in Chemours in the 3rd quarter valued at $35,000. Brooklyn Investment Group purchased a new stake in shares of Chemours during the 3rd quarter valued at $37,000. Finally, Signaturefd LLC raised its stake in shares of Chemours by 163.7% during the 3rd quarter. Signaturefd LLC now owns 1,959 shares of the specialty chemicals company’s stock worth $40,000 after purchasing an additional 1,216 shares during the period. 76.26% of the stock is currently owned by institutional investors.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.